Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$0.86
$0.03(2.88%)
At close: 4:00 PM EDT
$0.86
$0.03(2.88%)
Day’s Range― - ―
52-Week Range$0.71 - $3.40
Previous Close$1.07
Volume153.44K
Average Volume (3M)105.94K
Market Cap
$25.59M
Enterprise Value$57.74
Total Cash (Recent Filing)$94.36K
Total Debt (Recent Filing)$1.76M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding26,654,366
10 Day Avg. Volume109,002
30 Day Avg. Volume105,945
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved Balance-Sheet LeverageThe sharp reduction in leverage improves financial flexibility and reduces balance-sheet risk compared with 2024. Although losses remain substantial, lower debt exposure may leave more capacity to fund development, manage obligations, and pursue partnerships without excessive financial strain.
Retained BioKey OwnershipRetaining approximately 85% of BioKey preserves ABVC’s economic exposure to a separately operated subsidiary while establishing a distinct corporate structure. This could support clearer asset development and financing paths, although the value depends on BioKey’s future execution and market access.
Pipeline Monetization ModelA pipeline monetization model can provide multiple routes to future value creation, including upfront payments, development milestones, and royalties without requiring ABVC to commercialize every asset alone. The breadth across CNS, oncology, and ophthalmology also creates several potential development avenues.
Bears Say
Absent And Unstable RevenueThe lack of established recurring revenue makes the business highly dependent on successfully advancing candidates and completing licensing or collaboration transactions. Revenue volatility also limits operating visibility and makes it difficult to build a self-sustaining commercial foundation over the next several quarters.
Deep Operating LossesLarge operating and net losses indicate that the current development platform is not yet producing economic returns. Persistently negative profitability can erode equity value, constrain reinvestment, and increase dependence on external funding or successful partnering to support ongoing clinical and corporate activities.
Persistent Cash BurnNegative operating and free cash flow show that ongoing activities are not self-funding, despite some improvement from earlier periods. Continued burn raises the importance of capital access, asset monetization, or partnership proceeds and could restrict the pace of pipeline development if funding is not secured.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.71 and its highest was $3.40 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $25.59M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 70 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,654,366 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.35% Mutual Funds
0.14% Other Institutional Investors
96.37% Public Companies and
Individual Investors